Discovering Dewpoint's protein organizers

Why Polaris backed Dewpoint Therapeutics $60M series A

An experienced team and a drug discovery platform targeting biomolecular condensates enabled Dewpoint Therapeutics to raise $60 million in a series A round led by founding investor Polaris Partners.

Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital and the Leaps by Bayer program of Bayer AG (Xetra:BAYN)

Read the full 456 word article

User Sign In